Read this company snapshot
Daily valuation snapshot
AstraZeneca PLC: source evidence dated 2026-10-09.
- Daily close (USD)
- $159.2
- Market capitalization (USD)
- $246,904,194,126.4
- Price / earnings (TTM)
- 24.13
- Price / book
- 5.07
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research AZN in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research AZN in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, Byetta, XIGDUO, Accolate, Accoleit, Vanticon, Beyfortus, Synagis, FluMist, tixagevimab and cilgavimab, and sipavibart. It also provides Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Bricanyl Turbuhaler, Rhinocort, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Breztri Aerosphere, Duaklir Genuair, Kavigale, Evusheld, Fluenz/FluMist, and Voydeya. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the United States, Europe, and Asia. It has a strategic agreement with Tempus to develop the largest multimodal foundation model in oncology. The company has a collaboration agreement with IonQ, Inc. for the development of quantum-accelerated computational chemistry workflow for healthcare, life sciences, and chemistry; and a strategic research collaboration with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications. AstraZeneca PLC was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing AZN with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $159.2 |
| Market capitalization (USD) | $246,904,194,126.4 |
| Price / earnings (TTM) | 24.13 |
| Price / book | 5.07 |
No matching rows. Clear the filter to see all records.
Read AZN's valuation metrics
Company size
AstraZeneca PLC's recorded market capitalization is $246,904,194,126.4. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
AZN's recorded P/E is 24.13: about $24.13 of share price for each $1 of trailing annual earnings per share. Compare that multiple with earnings growth and companies in the same business.
Price relative to book equity
AZN's recorded price-to-book ratio is 5.07. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research AstraZeneca PLC with Aurora
Use the snapshot above to ask a specific question about AZN. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow AZN's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.